James Callaway
Directeur/Membre du Conseil chez XENETIC BIOSCIENCES, INC.
Fortune : - $ au 30/04/2024
Profil
Dr. James E.
Callaway is an Independent Director at Kalgene Pharmaceuticals, Inc., an Independent Non-Executive Director at Xenetic Biosciences, Inc. and an Independent Director at NURAVAX, INC.
He is on the Board of Directors at Kalgene Pharmaceuticals, Inc., Xenetic Biosciences, Inc. and NURAVAX, INC.
Dr. Callaway was previously employed as a President & Chief Executive Officer by ArmaGen Technologies, Inc., a President & Chief Executive Officer by Cebix, Inc., a Corporate Strategy Consultant by Callaway Innovations, and a Head-Development by Elan Pharmaceuticals LLC.
He received his doctorate degree from the University of California.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de James Callaway
| Sociétés | Poste | Début |
|---|---|---|
| XENETIC BIOSCIENCES, INC. | Directeur/Membre du Conseil | 14/08/2017 |
Kalgene Pharmaceuticals, Inc.
 Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Directeur/Membre du Conseil | 01/04/2020 |
NURAVAX, INC.
 NURAVAX, INC. Miscellaneous Commercial ServicesCommercial Services The American company specializes in immunotherapy for neurodegenerative disorders. Nuravax aims to create a new segment in the market for the preventive treatment of Alzheimer's disease (AD) and Parkinson's disease (PD) by developing safe and highly immunogenic preventive vaccines for preclinical PD/DLB and AD people based on a set of novel non-invasive and accurate disease biomarkers. The private company estimates the size of this market as approximately 40 million preclinical AD people at risk of disease. Nuravax is licensed for the patented multitep platform technology for the commercialization of prophylactic vaccines against all neurodegenerative disorders. The company is responsible for implementing co-development and sub-licensing agreements with larger biotech and pharmaceutical companies, and for further clinical validation of products. | Directeur/Membre du Conseil | - |
Anciens postes connus de James Callaway
| Sociétés | Poste | Fin |
|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Directeur Général | 01/01/2016 |
Cebix, Inc.
 Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Directeur Général | 01/01/2012 |
| Callaway Innovations | Corporate Officer/Principal | - |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Formation de James Callaway
| University of California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XENETIC BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Health Services |
NURAVAX, INC.
NURAVAX, INC. Miscellaneous Commercial ServicesCommercial Services The American company specializes in immunotherapy for neurodegenerative disorders. Nuravax aims to create a new segment in the market for the preventive treatment of Alzheimer's disease (AD) and Parkinson's disease (PD) by developing safe and highly immunogenic preventive vaccines for preclinical PD/DLB and AD people based on a set of novel non-invasive and accurate disease biomarkers. The private company estimates the size of this market as approximately 40 million preclinical AD people at risk of disease. Nuravax is licensed for the patented multitep platform technology for the commercialization of prophylactic vaccines against all neurodegenerative disorders. The company is responsible for implementing co-development and sub-licensing agreements with larger biotech and pharmaceutical companies, and for further clinical validation of products. | Commercial Services |
| Callaway Innovations |